Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG versus NOVOLOG MIX 70 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG versus NOVOLOG MIX 70 30.
NOVOLOG vs NOVOLOG MIX 70/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by binding to insulin receptors, enhancing peripheral glucose uptake, and inhibiting hepatic glucose production.
Biphasic insulin analog combining rapid-acting insulin aspart and intermediate-acting protamine-crystallized insulin aspart, which lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production.
Subcutaneous injection: 0.5-1 unit/kg/day divided into 3 or more doses given within 15 minutes before or after meals. Typical total daily dose range 0.5-1.5 units/kg.
Subcutaneous injection only. Typical total daily insulin dose ranges from 0.5 to 1.0 units/kg/day divided into two or three injections. Administer twice daily, with each dose given within 15 minutes before meals. Dose individualization based on glycemic targets and previous insulin regimen is required.
None Documented
None Documented
Terminal elimination half-life is 1.2-1.5 hours in healthy individuals, reflecting rapid clearance. In renal impairment (e.g., eGFR <30 mL/min), half-life may be prolonged up to 2-3 hours due to reduced degradation.
Insulin aspart (free component): ~1-2 hours; protamine-crystallized component: ~8-10 hours. Clinical context: Duration of action up to 24 hours due to the intermediate-acting component.
Renal excretion accounts for approximately 60-80% of insulin aspart degradation products; unchanged drug is minimally excreted. Biliary/fecal excretion is negligible (<10%).
Renal: 30-80% of dose excreted unchanged in urine for insulin aspart; for protamine-crystallized component, metabolism and renal elimination also occur. Biliary/fecal: Minor.
Category C
Category C
Insulin Analog
Insulin Analog